US Patent

US11542239 — Elagolix sodium compositions and processes

Composition of Matter · Assigned to AbbVie Inc · Expires 2039-07-23 · 13y remaining

Vulnerability score 12/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compositions of elagolix sodium, processes for preparing it, and intermediates involved in its preparation.

USPTO Abstract

The present invention relates to compositions of elagolix sodium, and process and intermediates for the preparation thereof.

Drugs covered by this patent

Patent Metadata

Patent number
US11542239
Jurisdiction
US
Classification
Composition of Matter
Expires
2039-07-23
Drug substance claim
Yes
Drug product claim
Yes
Assignee
AbbVie Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.